Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction

Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	M. A. Cherepanova
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2018
Materias:	type 2 diabetes liver linagliptin apoptosis Science Q
Acceso en línea:	https://doaj.org/article/885df33e57d1482cb29c0868ac9d9967
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:885df33e57d1482cb29c0868ac9d9967
record_format	dspace
spelling	oai:doaj.org-article:885df33e57d1482cb29c0868ac9d99672021-11-23T06:14:40ZPeculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction2541-94202587-959610.29413/ABS.2018-3.1.18https://doaj.org/article/885df33e57d1482cb29c0868ac9d99672018-02-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/547https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the developing of NAFLD is a dysfunction of hematolymphatic barrier and linagliptin showed positive effect on this. The group of inhibitors of apoptosis - Bcl-2 resists to wide variety of pro-apoptotic proteins. Studying correction of apoptosis can be the key to the treatment of NAFLD, and that is a reason of high interest in anti-apoptotic Bcl-2 protein. Aims. To assess the features of the expression of the anti-apoptotic Bcl-2 protein in the liver of db/db mice in the model of obesity and type 2 diabetes mellitus and with linaglyptin correction. Materials and methods. Experiment was performed on type 11 (db/db) diabetic mice. Linaglyptin or placebo was administered daily by gavage from the 8th to 16th weeks of life. Results. The week immunohistochemical reaction for antiapoptotic protein Bcl-2 was found in placebo-treated mice. Whereas treatment with Linaglyptin shifted the ratio of apoptosis regulators following significant increase in the area of Bcl-2 expression. Conclusions. The obtained results demonstrate a "try" at antiapoptotic activity of the Linaglyptin in the liver in the model of T2D.M. A. CherepanovaScientific Сentre for Family Health and Human Reproduction Problemsarticletype 2 diabetesliverlinagliptinapoptosisScienceQRUActa Biomedica Scientifica, Vol 3, Iss 1, Pp 116-119 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	type 2 diabetes liver linagliptin apoptosis Science Q
spellingShingle	type 2 diabetes liver linagliptin apoptosis Science Q M. A. Cherepanova Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
description	Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the developing of NAFLD is a dysfunction of hematolymphatic barrier and linagliptin showed positive effect on this. The group of inhibitors of apoptosis - Bcl-2 resists to wide variety of pro-apoptotic proteins. Studying correction of apoptosis can be the key to the treatment of NAFLD, and that is a reason of high interest in anti-apoptotic Bcl-2 protein. Aims. To assess the features of the expression of the anti-apoptotic Bcl-2 protein in the liver of db/db mice in the model of obesity and type 2 diabetes mellitus and with linaglyptin correction. Materials and methods. Experiment was performed on type 11 (db/db) diabetic mice. Linaglyptin or placebo was administered daily by gavage from the 8th to 16th weeks of life. Results. The week immunohistochemical reaction for antiapoptotic protein Bcl-2 was found in placebo-treated mice. Whereas treatment with Linaglyptin shifted the ratio of apoptosis regulators following significant increase in the area of Bcl-2 expression. Conclusions. The obtained results demonstrate a "try" at antiapoptotic activity of the Linaglyptin in the liver in the model of T2D.
format	article
author	M. A. Cherepanova
author_facet	M. A. Cherepanova
author_sort	M. A. Cherepanova
title	Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
title_short	Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
title_full	Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
title_fullStr	Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
title_full_unstemmed	Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
title_sort	peculiarities of the antiapoptotic bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2018
url	https://doaj.org/article/885df33e57d1482cb29c0868ac9d9967
work_keys_str_mv	AT macherepanova peculiaritiesoftheantiapoptoticbcl2proteinexpressioninliverinamodelofobesityandtype2diabetesandwithlinaglyptincorrection
_version_	1718416956893167616

Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction

Ejemplares similares